ReviewJournal of Cancer2019
Interleukin-35 as an Emerging Player in Tumor Microenvironment.
Review in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Role of serum IL-35 levels in patients with benign and malignant primary ovarian tumors: a case-control study.Scientific reports · 2025Article
- Impacts of rs7528684 (-169T/C) onFrontiers in genetics · 2025Article
- Development of Functional Foods: A Comparative Study on the Polyphenols and Anthocyanins Content in Chokeberry and Blueberry Pomace Extracts and Their Antitumor Properties.Foods (Basel, Switzerland) · 2024Article
- Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.Oncogene · 2024Article
- Article
- Estimating the salivary levels of IL-35 in smokers with periodontitis: A cross sectional study.The Saudi dental journal · 2024Article
- Biomolecules Involved in Both Metastasis and Placenta Accreta Spectrum-Does the Common Pathophysiological Pathway Exist?Cancers · 2023Review
- JNK/c-Jun pathway activation is essential for HBx-induced IL-35 elevation to promote persistent HBV infection.Journal of clinical laboratory analysis · 2023Article
- Serum Interleukins as Potential Prognostic Biomarkers in HBV-Related Acute-on-Chronic Liver Failure.Mediators of inflammation · 2022Review
- The Molecular Role of IL-35 in Non-Small Cell Lung Cancer.Frontiers in oncology · 2022Review
- Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.Clinical and experimental immunology · 2021Article
- Targeting Oncoimmune Drivers of Cancer Metastasis.Cancers · 2021Review
- IL-12 Family Cytokines in Cancer and Immunotherapy.Cancers · 2021Review
- Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation.Oxidative medicine and cellular longevity · 2021Review
- IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.Frontiers in cell and developmental biology · 2021Review
- Interleukin-35 Suppresses CD8Digestive diseases and sciences · 2020Article
- Curcumin Promotes the Expression of IL-35 by Regulating Regulatory T Cell Differentiation and Restrains Uncontrolled Inflammation and Lung Injury in Mice.Inflammation · 2020Article
- Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-35 is the newest member of IL-12 family. A dimeric protein consisting of two separate subunits has manifested suppressive actions on immune system, which is counterproductive in the context of cancers. Various reports have confirmed its inhibitory role on immune system which is carried out via formation of IL-35-producing regulatory T cells (iTr35), increased Treg development and suppressive Th17 cells growth. Although last decade has seen a great deal of scientific interest on this subject, the exact role, precise signal transduction and elaborative functions of IL-35 in tumor microenvironment (TME) remained elusive. Search for anti-IL-35 therapies have exhibited limited success in animal models. Contrarily, few studies have denied the idea that IL-35 plays a role in cancer. The purpose of this review is to analyze the reported scientific data on continuous symphony of IL-35 in cancers since the inception of former.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.